A review of rifaximin and bacterial overgrowth in poorly responsive celiac disease
- 27 September 2011
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 5 (1), 31-36
- https://doi.org/10.1177/1756283x11422264
Abstract
A proportion of patients with celiac disease have a poor response to a gluten-free diet, which may be due to small-intestinal bacterial overgrowth (SIBO). Treatment with rifaximin is often used in the clinical setting, but there is limited literature to support this practice. In addition, challenges in the diagnosis of SIBO confound response interpretation. Our recent placebo-controlled trial did not demonstrate any improvement in gastrointestinal symptoms after treatment with rifaximin and casts doubt on the utility of lactulose–hydrogen breath testing for SIBO in this population.Keywords
This publication has 47 references indexed in Scilit:
- Double-Blind Randomized Controlled Trial of Rifaximin for Persistent Symptoms in Patients with Celiac DiseaseDigestive Diseases and Sciences, 2011
- Review article: small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoeaAlimentary Pharmacology & Therapeutics, 2009
- Methodology and Indications of H2‐Breath Testing in Gastrointestinal Diseases: the Rome Consensus ConferenceAlimentary Pharmacology & Therapeutics, 2009
- Prevalence of Small Intestine Bacterial Overgrowth Diagnosed by Quantitative Culture of Intestinal Aspirate in Celiac DiseaseJournal of Clinical Gastroenterology, 2009
- Editors’ declarations of interestAlimentary Pharmacology & Therapeutics, 2009
- A Systematic Review of Diagnostic Tests for Small Intestinal Bacterial OvergrowthDigestive Diseases and Sciences, 2007
- High dosage rifaximin for the treatment of small intestinal bacterial overgrowthAlimentary Pharmacology & Therapeutics, 2007
- Small Intestinal Bacterial Overgrowth: Roles of Antibiotics, Prebiotics, and ProbioticsGastroenterology, 2006
- Rifaximin, a Peculiar Rifamycin Derivative: Established and Potential Clinical Use Outside the Gastrointestinal TractChemotherapy, 2005
- Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphomaThe Lancet, 2000